secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001493152-24-009437
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa receives Nasdaq reprimand for July 2023 offering; proposes reverse stock split to cure bid price deficiency
--------------------------------------------------------------------------------

- Nasdaq staff determined July 2023 offering required stockholder approval; issued Letter of Reprimand, no further action.
- Company must cure bid price deficiency by May 3, 2024 to avoid delisting from Nasdaq.
- Special stockholders meeting on April 17, 2024 to vote on reverse stock split of 1:2 to 1:50.
- Company believes recent NLRP3 inhibitor data and upcoming phase 2a trial may raise stock price above $1.00, avoiding reverse split.
- Board retains right to abandon reverse stock split if bid price deficiency cured by other means.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315224009437/0001493152-24-009437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315224009437/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer